Bayer’s new CEO may be considering some valuable crop rotation. The 49 billion euro seed-to-drug maker’s shares rallied 3% on Monday after a Friday report by German news service Platow Brief said the company may spin off its troubled crop science division. For new boss Bill Anderson, the numbers certainly work. Bayer’s component parts, valued separately on peer multiples, would have a total equity value of 96 billion euros, Breakingviews calculated in February, or almost double the group’s current market capitalisation. Admittedly crop-science rival Corteva has dropped since then, but not enough to change the overall logic.
[#translated_full_content] [#item_full_content]